|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These data suggest that concomitant allelic losses of the BRCA1 and FHIT genes are associated with more aggressive breast tumors.
|
20417865 |
2010 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
|
19130459 |
2009 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Importance of novel sequence alterations in the FHIT gene on formation of breast cancer.
|
18338496 |
2008 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of Afadin was correlated with loss of FHIT expression, suggesting fragility of FRA6E and FRA3B in a certain proportion of breast tumors.
|
16819513 |
2007 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Concordant loss of fragile gene expression early in breast cancer development.
|
15998374 |
2005 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
|
15073846 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer.
|
14566838 |
2003 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
LHGDN |
Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
|
12231533 |
2002 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Abnormal FHIT gene transcript and c-myc and c-erbB2 amplification in breast cancer.
|
12362975 |
2002 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
[Loss of fragile histidine triad expression and metastasis in breast cancer].
|
12452072 |
2002 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
|
12353263 |
2002 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The FHIT gene is located at the FRA 3B fragile site at chromosome 3p 14.2, and alterations in the FHIT gene and Fhit protein have been found associated with genome instability, particularly in BRCA 2 mutated breast tumours.
|
11562178 |
2001 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LOH at FHIT is associated with estrogen- and progesterone-negative breast tumors, high S-phase fraction, reduced patient survival, and LOH at chromosome regions 6q, 7q, 8p, 9p, 11p, 11q, 13q, 16q, 17p, 17q, 18q, and 20q.
|
11425271 |
2001 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Analysis of 27 ovarian tumors demonstrating both loss and retention of 3p markers enabled us to define four nonoverlapping minimal deletion regions (OCLOHRs): (a) OCLOHR-1 mapped distal to D3S3591 at 3p25-26; (b) OCLOHR-2 mapped between D3S1317 and D3S1259 at 3p24-25; (c) OCLOHR-3 mapped between D3S1300 and D3S1284, an area that includes the FHIT locus at 3p14.2; and (d) OCLOHR-4 mapped between D3S1284 and D3S1274 at 3p12-13, a region known to contain overlapping homozygous deletions in lung and breast tumor cell lines.
|
10493522 |
1999 |